Compare LYFT Inc (LYFT) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs ResMed Inc. — how do they compare? LYFT Inc trades at $15.21 (market cap $5.86B), while ResMed Inc. trades at $195.32 (market cap $28.81B). The key difference: ResMed Inc. is far larger — about 4.9× LYFT Inc's market cap, and ResMed Inc. pays a 1.21% dividend while LYFT Inc pays none. Which is the better fit depends on your goals.
| LYFT | RMD | |
|---|---|---|
Market Cap | $5.86B | $28.81B |
Sector | Industrials | Health |
52-Week High | $24.57 | $293.73 |
52-Week Low | $12.65 | $182.82 |
Enterprise Value | $5.39B | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft trades at $15.39, down 0.84% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company demonstrates strong revenue growth, reaching $6.32B in 2025 with a remarkable net income margin of 43.82%, though recent quarterly EPS results have been inconsistent with two misses and one beat. Analyst consensus leans neutral with 57.6% hold ratings but offers a $17.86 price target suggesting 16% upside potential.
Lyft presents a compelling valuation case with a low P/E of 2.27 and P/S of 0.98, supported by improving cash flow trends and strategic expansions into new markets. However, risks include competitive pressure from Uber, inconsistent earnings performance, and regulatory scrutiny over pricing practices. The upcoming Q2 2026 earnings report on August 6 will be critical for validating the company's growth trajectory.
ResMed (RMD) trades at $198.61, down 0.19% on the day, with a neutral technical signal and bearish moving averages. The company shows strong fundamentals, with Q1 2026 EPS beating estimates at $2.86 and revenue growth from $5.15B in 2025 to a projected $5.5B in 2026. Recent news highlights the sale of its MatrixCare business for $490 million, sharpening focus on core sleep and respiratory care markets. Analyst consensus is a Buy with a $245.88 price target, implying significant upside.
The outlook for RMD is positive, driven by consistent earnings beats, robust cash flow growth, and strategic divestitures. Key opportunities include market leadership in sleep apnea and digital health innovation. Risks involve competitive pressures from GLP-1 drugs and macroeconomic headwinds. Institutional sentiment is mixed but leans bullish on long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
